<DOC>
	<DOCNO>NCT02702856</DOCNO>
	<brief_summary>Validate non-DRE exosome gene expression test , NPV &gt; /= 90 % certainty , exclude presence high gleason grade/ score ( &gt; /=7 ) prostate cancer prostate needle biopsy .</brief_summary>
	<brief_title>Clinical Validation Urinary Exosome Gene Signature Men Presenting Suspicion Prostate Cancer</brief_title>
	<detailed_description>The purpose multi-center clinical study determine association Exosome Urine Test score presence high Gleason grade / score ( GS &gt; /=7 ) prostate cancer prostate needle biopsy validate assay 's performance characteristic men present urologist without previous negative biopsy , recommend initial subsequent biopsy . The result study support use assay laboratory developed test . A secondary objective develop assay accurately predict presence Gleason grade prostate cancer men risk prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Male , &gt; 50 year age clinical suspicion prostate cancer base part elevate PSA ( limit range : 2.0 20 ng/ mL ) , suspicious DRE , without clinical history single prior negative biopsy , recommend repeat first time biopsy . 2 . The subject must able comprehend sign approve informed consent form applicable study document . 1 . Use medication hormone know affect serum PSA level within 36 month study enrollment . 2 . Clinical symptom urinary tract infection ( include prostatitis ) time enrollment . 3 . History prostate cancer . 4 . History invasive treatment benign prostatic hypertrophy ( BPH ) low urinary track symptom within 6 month study enrollment . 5 . Medical history concurrent illness investigator considers sufficiently serious interfere conduct , completion result trial , constitute unacceptable risk subject . 6 . Participation pharmaceutical treatment related clinical study within 6 month study enrollment . Exception : Trials nonprostate condition may acceptable , approval investigator Sponsor . 7 . No known hepatitis ( type ) and/or HIV document patient 's medical record . 8 . Patients history concurrent renal/bladder tumor within 6 month study enrollment .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Gleason Grade</keyword>
	<keyword>Prostatic Neoplasms</keyword>
</DOC>